Real-world results confirm benefit of antigen therapy for prostate cancer

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is harmless and effectual for patients with metastatic castration-resistant prostate crab (mCRPC) successful regular objective practice, accordant with outcomes from the VISION trial. An investigation of outcomes from a French early-access program, the largest real-world cohort of patients studied to date, confirms the benefit-risk illustration of the therapy, portion besides shedding airy connected diligent enactment and usage trends. This probe was published successful The Journal of Nuclear Medicine.